Theophylline in copd
Reading File
Finding Sources
Searching PubMed
theophylline AND COPD
Searching the Web
GOLD COPD 2026 theophylline recommendations
Reading File
Reading File
Reading Article
PMID: 40327637
Reading Web Page
https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-…
Theophylline in COPD
Theophylline is not a routine first-line treatment for COPD. Inhaled long-acting bronchodilators, especially LAMA or LAMA-LABA therapy, are preferred because they are more effective and substantially safer.
Role in stable COPD
Theophylline is an oral methylxanthine with modest bronchodilator effects. It may occasionally be considered as an add-on when symptoms remain troublesome despite optimal inhaled treatment, particularly where inhaled options are unavailable or unaffordable.
- It can produce small improvements in FEV1 and breathlessness.
- It has not consistently reduced exacerbations, especially when low-dose theophylline is added to inhaled corticosteroids.
- It should not replace appropriate inhaled LAMA, LABA, or LAMA-LABA treatment.
- Sustained-release formulations are the preparations studied in COPD.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 904
A 2025 systematic review of 10 RCTs (2,771 patients) found small spirometric improvements and fewer exacerbations with add-on oral theophylline, but also significantly more adverse drug reactions, especially gastrointestinal effects. See the 2025 meta-analysis.
Not recommended in acute COPD exacerbation
IV aminophylline or theophylline should not be used routinely in acute exacerbations of COPD, because benefits are limited and adverse effects can be serious. The current GOLD 2026 report specifically advises against intravenous methylxanthines in this setting.
Why its use is limited
Theophylline has a narrow therapeutic index and many clinically important interactions. Toxicity is concentration-related.
| Adverse effects | Severe toxicity |
|---|---|
| Nausea, vomiting, reflux, abdominal discomfort | Atrial or ventricular arrhythmias |
| Headache, tremor, insomnia, agitation | Hypotension |
| Palpitations | Seizures, potentially fatal |
Adverse effects commonly emerge at serum levels above about 15 mg/L. Lower levels, often around 5-10 mg/L, are used if treatment is chosen, but monitoring practices and target levels should be individualized by the prescribing clinician.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 904
Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 904
Important interactions and factors affecting clearance
Theophylline concentrations can rise dangerously with drugs such as:
- Ciprofloxacin and some other quinolones
- Erythromycin and some macrolides
- Cimetidine
- Allopurinol
- Some antidepressants, including fluvoxamine
Clearance is reduced in older age, liver disease, heart failure, fever, and acute illness. It is increased by cigarette smoking. Therefore, someone who stops smoking while taking theophylline may develop toxic levels unless their dose is reviewed.
The Washington Manual of Medical Therapeutics, p. 319
The Washington Manual of Medical Therapeutics, p. 319
Bottom line
Use theophylline in COPD only selectively, usually as a carefully monitored add-on when preferred inhaled therapies are inadequate, inaccessible, or unsuitable. It is generally avoided because the symptomatic benefit is limited relative to its interaction burden and risk of arrhythmia or seizures.
High flow oxygen therapy in copd
Reading File
Finding Sources
Searching PubMed
COPD AND high-flow nasal cannula
Searching the Web
GOLD 2026 COPD exacerbation oxygen target saturation 88 92 high flow nasal therapy
Finding Sources
Reading Article
PMID: 40859250
Reading Article
PMID: 42471821
Reading Web Page
https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-…
Reading File
Reading File
Finding Sources
High-flow oxygen therapy in COPD
“High-flow oxygen” can mean either uncontrolled high-concentration oxygen or high-flow nasal cannula therapy (HFNC/HFNT). In COPD, these must be distinguished.
1. Controlled oxygen is the priority in acute COPD exacerbation
For hypoxemic COPD exacerbations, give supplemental oxygen but titrate it to SpO₂ 88%-92%. Check arterial blood gases, especially if the patient is drowsy, severely unwell, or has known CO₂ retention.
Avoid routinely aiming for 98%-100% saturation. Excess oxygen can worsen hypercapnia through worsened ventilation-perfusion mismatch, the Haldane effect, and, in some people, reduced ventilatory drive. A Venturi mask offers controlled, predictable FiO₂ delivery.
ROSEN's Emergency Medicine: Concepts and Clinical Practice, p. 947
The Washington Manual of Medical Therapeutics, p. 319
ROSEN's Emergency Medicine: Concepts and Clinical Practice, p. 947
The Washington Manual of Medical Therapeutics, p. 319
2. What is HFNC?
HFNC delivers heated, humidified air-oxygen through wide nasal cannulae, usually at 10-60 L/min, with adjustable FiO₂. Potential benefits include:
- Better comfort and secretion clearance than a tight NIV mask
- Reduced respiratory rate and work of breathing
- Washout of upper-airway dead space, which may reduce PaCO₂
- A small positive airway pressure effect
- More stable oxygen delivery than ordinary nasal cannula oxygen
The GOLD 2026 report describes HFNC as an option when conventional oxygen does not adequately correct hypoxemia, when hypercapnia is present, or when NIV cannot be tolerated.
3. HFNC versus NIV in hypercapnic COPD
NIV, usually bilevel positive airway pressure (BiPAP), remains first-line ventilatory support for an acute COPD exacerbation with hypercapnic respiratory failure and respiratory acidosis, such as PaCO₂ >45 mmHg with pH <7.35.
HFNC may be reasonable in:
- Mild or moderate hypercapnia without significant acidosis
- Persistent hypoxemia despite conventional oxygen
- NIV intolerance, for example claustrophobia, mask discomfort, pressure sores
- Breaks from NIV, or selected post-extubation patients
- A closely monitored setting with a defined plan to escalate to NIV or intubation if deterioration occurs
HFNC should not delay NIV in a patient with worsening acidosis, rising PaCO₂, exhaustion, impaired consciousness, or increasing respiratory distress.
A 2025 meta-analysis of nine RCTs found no significant difference in mortality or intubation between HFNC and NIV, but showed a trend toward more treatment failure with HFNC, while HFNC was better tolerated. See the HFNC versus NIV meta-analysis. A 2026 systematic review similarly concluded that HFNC is less effective than NIV in severe hypercapnic failure, although it can be useful in milder cases or when NIV is not tolerated. See the 2026 systematic review.
Practical summary
| Situation | Preferred support |
|---|---|
| Hypoxemia without ventilatory failure | Controlled oxygen, target SpO₂ 88%-92% |
| Hypercapnic respiratory acidosis | NIV/BiPAP first-line |
| Mild hypercapnia or NIV intolerance | Consider HFNC with close monitoring |
| Worsening acidosis, fatigue, reduced consciousness, NIV failure | Escalate urgently to invasive ventilation assessment |
Long-term home use
HFNC is not standard long-term oxygen therapy. Standard LTOT is indicated for severe chronic resting hypoxemia, generally PaO₂ ≤55 mmHg or SpO₂ ≤88%, and is usually prescribed for at least 15 hours/day. Selected patients with chronic hypercapnic COPD may benefit from home HFNC in specialist care, but this is not routine.
Fishman's Pulmonary Diseases and Disorders, Long-Term Oxygen Therapy, p. 3418
Fishman's Pulmonary Diseases and Disorders, Long-Term Oxygen Therapy, p. 3418
This is a shared conversation. Sign in to Orris to start your own chat.